91ºÚÁÏ experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ¡®Category¡¯ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Dr. Peter Schueler explores how .
-
Shelley McLendon considers the knock-on effect of COVID-19 for other infectious diseases, and what we can do to speed up development future vaccines
-
In this article, CFO Brendan Brennan discusses the responsibility of CROs in the fight against COVID-19, particularly by helping the most vulnerable populations gain access to vaccines and treatments.
-
In this radio interview briefly discusses the disparity of vaccine rollouts of developed countries compared to less economically developed countries, and the role of 91ºÚÁÏ
-
In this podcast, Martin Lachs discusses how clinical trials have been the backbone of cancer research.
-
In this webinar review some of the factors investigational teams should now consider in the planning and execution of cell and gene therapy development programs.
-
91ºÚÁÏ CEO, Dr. Steve Cutler offers his perspective of the ever-changing CRO landscape based on recent mergers and acquisitions in the industry.
-
Chris O'Toole considers the challenges that pharma companies may face when adopting a more patient-centric approach.
-
This article reports on 91ºÚÁÏ¡¯s multimillion-euro funding from the Irish government to enhance its decentralised and hybrid trial capabilities.
-
91ºÚÁÏ has received €4m in R&D investment from the Irish government to further develop its technology for decentralised and hybrid clinical trials.
